Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19058309 | Isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof | February 2025 | May 2025 | Allow | 3 | 0 | 0 | No | No |
| 18865727 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | November 2024 | April 2025 | Allow | 5 | 0 | 0 | No | No |
| 18883472 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | September 2024 | November 2024 | Allow | 2 | 0 | 0 | No | No |
| 18758102 | METHODS OF TREATING MOOD DISORDERS | June 2024 | October 2025 | Allow | 15 | 1 | 0 | No | No |
| 18742840 | CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBIN | June 2024 | June 2025 | Allow | 12 | 1 | 0 | No | No |
| 18738245 | METHOD FOR MANUFACTURING AROMATIC NITRILE COMPOUND | June 2024 | March 2026 | Allow | 21 | 1 | 0 | No | No |
| 18717094 | PSILOCYBIN DERIVATIVES | June 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18680473 | METHODS OF TREATING MOOD DISORDERS | May 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18644754 | NOVEL BENZYLTRYPTAMINE COMPOUNDS | April 2024 | July 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18624982 | POLYMORPHIC COMPOUNDS AND USES THEREOF | April 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18621972 | POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18621997 | SILICON CONTAINING DETECTABLE COMPOUNDS AND USES THEREOF | March 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18614136 | NOVEL CRYSTALLINE SALT FORMS OF MESEMBRINE | March 2024 | December 2025 | Allow | 21 | 1 | 0 | No | No |
| 18604747 | ORGANIC COMPOUND SALTS | March 2024 | May 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18600018 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | March 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18590523 | LEUKOTRIENE SYNTHESIS INHIBITORS | February 2024 | March 2026 | Allow | 25 | 2 | 0 | No | No |
| 18438838 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18418560 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | January 2024 | October 2024 | Allow | 8 | 0 | 0 | No | No |
| 18417291 | ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF | January 2024 | July 2025 | Allow | 18 | 2 | 0 | No | No |
| 18414958 | CRYSTAL FORMS OF IMMUNOMODULATORS | January 2024 | November 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18542220 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18534253 | MALASSEZIN AND ANALOGS THEREOF AS SKIN BRIGHTENING AGENTS | December 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18532752 | OXYSTEROLS AND METHODS OF USE THEREOF | December 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18517432 | METHODS OF TREATING MUTANT LYMPHOMAS | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18510718 | Process for Preparing Large Size Isoxazoline Particles | November 2023 | December 2025 | Allow | 25 | 1 | 1 | No | No |
| 18500247 | PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | November 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18384815 | 4,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(4-HYDROXY-3-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18495288 | 4-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18493231 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | October 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18484211 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | October 2023 | June 2024 | Abandon | 8 | 1 | 0 | No | No |
| 18375003 | SULFONAMIDE DERIVATIVES FOR PROTEIN DEGRADATION | September 2023 | October 2025 | Allow | 24 | 2 | 1 | No | No |
| 18373518 | COMPOUNDS AND USES THEREOF | September 2023 | July 2025 | Allow | 22 | 2 | 0 | No | No |
| 18469032 | Carbamoyl Phenylalaninol Compounds and Uses Thereof | September 2023 | November 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18467022 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | September 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18465464 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | September 2023 | January 2026 | Allow | 28 | 2 | 1 | No | No |
| 18462355 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | September 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18453431 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | August 2023 | October 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18234629 | SYNTHESIS METHOD FOR N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLAMIDE DERIVATIVE AND N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLIC ACID | August 2023 | August 2024 | Allow | 12 | 3 | 0 | No | No |
| 18546509 | AQUEOUS COMPOSITIONS COMPRISING 6-UNDECANOL-ESTERS | August 2023 | February 2026 | Allow | 30 | 1 | 0 | No | No |
| 18233160 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | August 2023 | November 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18366553 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | August 2023 | September 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18227325 | N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | July 2023 | March 2025 | Allow | 20 | 2 | 0 | No | No |
| 18218216 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | July 2023 | May 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18268144 | SOLID FORMS OF A COMPOUND | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18336562 | TEAD INHIBITORS AND USES THEREOF | June 2023 | November 2025 | Allow | 29 | 2 | 1 | No | No |
| 18327990 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | June 2023 | March 2025 | Allow | 22 | 2 | 0 | No | No |
| 18204870 | CRYSTALLINE FORMS OF COMPOSITIONS COMPRISING PSILOCIN AND PSILOCYBIN | June 2023 | March 2024 | Allow | 9 | 1 | 0 | No | No |
| 18039108 | DELAYED FLUORESCENCE COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | May 2023 | November 2025 | Allow | 29 | 0 | 0 | No | No |
| 18038680 | PLATINUM COMPLEX HAVING ONCN TETRADENTATE LIGAND AND CONTAINING CARBAZOLE | May 2023 | December 2025 | Allow | 31 | 1 | 0 | No | No |
| 18254375 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18322323 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION METHOD THEREOF | May 2023 | November 2025 | Allow | 30 | 1 | 0 | No | No |
| 18253808 | FUNGICIDAL ARYL AMIDINES | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18197414 | CRYSTALLINE FORMS OF 3-SUBSTITUTED 1,2,4- OXADIAZOLE | May 2023 | August 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18252949 | INHALABLE FORMULATIONS | May 2023 | September 2025 | Allow | 28 | 1 | 0 | No | No |
| 18317169 | CRYSTALLINE BIS-MIPROCIN FUMARATE | May 2023 | April 2024 | Allow | 11 | 1 | 0 | No | No |
| 18313365 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18313040 | SMARCA DEGRADERS AND USES THEREOF | May 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18142662 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PSILOCIN AND USES THEREOF | May 2023 | June 2025 | Allow | 25 | 3 | 0 | No | No |
| 18310822 | PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | May 2023 | November 2025 | Abandon | 31 | 2 | 0 | No | Yes |
| 18251452 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18141844 | Novel Psilocin Analog Compositions And Methods of Synthesizing The Same | May 2023 | October 2024 | Abandon | 18 | 3 | 0 | No | No |
| 18309065 | HYDROXYBENZAMIDE DERIVATIVES AND METHODS OF USE IN TREATING DIABETES | April 2023 | November 2025 | Allow | 31 | 1 | 0 | No | No |
| 18034099 | DEUTERATED AMINOTHIAZOLE COMPOUNDS AS ANTIVIRAL COMPOUNDS | April 2023 | December 2025 | Allow | 31 | 1 | 0 | No | No |
| 18033943 | Process for Preparing 1,2-Benzisothiazoline-3-One | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18031296 | GEL FORMULATIONS COMPRISING MONTELUKAST | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18030962 | SMALL MOLECULE COMPOUND SERVING AS JAK KINASE INHIBITOR, AND USE THEREOF | April 2023 | December 2025 | Allow | 32 | 1 | 0 | No | No |
| 18030181 | POTENT AND SELECTIVE COVALENT INHIBITORS OF SERINE-ARGININE PROTEIN KINASE (SRPK) 1 AND SRPK2 AND USES THEREOF | April 2023 | August 2025 | Allow | 28 | 0 | 0 | No | No |
| 18129725 | CRYSTALLINE SALT FORMS OF MESEMBRINE | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18027890 | HYDROXYLBENZYL AZABICYCLO[2.2.1]HEPTAN-1-ANE DRIVATIVES AND MEDICAL USES THEREOF | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18179622 | Compounds Useful for Treating Liver Diseases | March 2023 | December 2024 | Allow | 21 | 0 | 1 | No | No |
| 18115942 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | March 2023 | September 2024 | Abandon | 19 | 2 | 0 | No | No |
| 18114959 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18173717 | N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF | February 2023 | July 2023 | Allow | 5 | 1 | 0 | No | No |
| 18172691 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | February 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18000939 | PREPARATION METHOD FOR CHLORINATED COMPOUND | February 2023 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 18170022 | HETEROCYCLIC COMPOUND | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18166934 | INTERMEDIATE COMPOUNDS AND METHODS | February 2023 | August 2024 | Allow | 18 | 2 | 0 | No | No |
| 18020448 | PROCESS FOR PREPARING SILOXANES | February 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18020492 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | February 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18163388 | DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | February 2023 | November 2024 | Allow | 22 | 2 | 0 | No | No |
| 18162375 | PLATINUM COMPOUNDS THAT INHIBIT CONSTITUTIVE STAT3 SIGNALING AND INDUCE CELL CYCLE ARREST AND APOPTOSIS OF MALIGNANT CELLS | January 2023 | January 2024 | Abandon | 12 | 1 | 0 | No | No |
| 18101387 | CRYSTAL FORMS OF IMMUNOMODULATORS | January 2023 | November 2023 | Allow | 9 | 1 | 0 | No | No |
| 18094001 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | January 2023 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18088692 | USE OF COLCHICINE TO INHIBIT TUMOR GROWTH AND METASTASES | December 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 18087672 | Treatment of Respiratory Diseases | December 2022 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 18011234 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | December 2022 | January 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 18011149 | FLUORENYL CYANINE DYES | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18001771 | PLASMA CONVERSION REACTOR OF C02 WITH C1 TO C4 HYDROCARBON TO C1 TO C5 OXYGENATE AND METHOD THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 18064324 | MOLECULAR SIEVE SSZ-116, ITS SYNTHESIS AND USE | December 2022 | July 2025 | Allow | 31 | 1 | 0 | No | No |
| 18001309 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18008818 | Substituted Benzimidazole Derivative And Use Thereof | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18062469 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | December 2022 | September 2023 | Allow | 10 | 1 | 0 | No | No |
| 17999931 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | November 2022 | August 2023 | Allow | 8 | 1 | 0 | No | No |
| 17993389 | ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF | November 2022 | January 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18058587 | PRODRUGS OF 4- ( (1R, 3S) -6-CHLORO-3-PHENYL-2, 3-DIHYDRO-1H-INDEN-1-YL) -1,2, 2-TRIMETHYLPIPERAZINE AND 4- ( (1R, 3S)-6-CHLORO-3- (PHENYL-D5) -2, 3-DIHYDRO-1H-INDEN-1-YL) -2, 2-DIMETHYL-1 (METHYL-D3) PIPERAZINE | November 2022 | April 2024 | Allow | 17 | 2 | 0 | No | No |
| 17927677 | POLYNORBORNENE/CARBON BLACK-CROSS-LINKED THREE-DIMENSIONAL NETWORK-IMMOBILIZED COPPER/GOLD (PNBI/CB-Cu/Au) NANOCATALYST, AND PREPARATION METHOD AND USE THEREOF | November 2022 | January 2026 | Allow | 38 | 2 | 0 | No | No |
| 17991875 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | November 2022 | June 2023 | Allow | 7 | 0 | 0 | No | No |
| 17992284 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | November 2022 | December 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17999310 | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE | November 2022 | December 2024 | Allow | 25 | 2 | 0 | No | No |
| 17998741 | ADMINISTRATION OF SUMO-ACTIVATING ENZYME INHIBITOR AND ANTI-CD38 ANTIBODIES | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JACKSON, SHAWQUIA.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JACKSON, SHAWQUIA works in Art Unit 1626 and has examined 1,949 patent applications in our dataset. With an allowance rate of 79.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner JACKSON, SHAWQUIA's allowance rate of 79.1% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by JACKSON, SHAWQUIA receive 1.56 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JACKSON, SHAWQUIA is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -7.5% benefit to allowance rate for applications examined by JACKSON, SHAWQUIA. This interview benefit is in the 4% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 37.9% of applications are subsequently allowed. This success rate is in the 87% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 71.7% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 89.4% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 92.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 65.0% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.8% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.